It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
The estrogen receptor (ER) is a member of the nuclear receptor superfamily and has two subtypes: ERα and ERβ. Inhibition of ERα is an effective therapeutic strategy in breast cancer. In contrast, ERβ is the presumed drug target of various autoimmune diseases. Many experimental structures of ERα/β have been reported; however, their structures vary due to ligand variability. Here, we performed structural bioinformatics studies for three-dimensional structures of ERs retrieved from the protein data bank (PDB) and clarify the detailed structural differences between ERα and ERβ. In total, 48 structures registered in the PDB were analyzed by HBOP and HBSITE, which we developed to identify ligand-binding cavities in proteins. PDB entries were clustered by number, shape, size, and location of the ligand-binding pockets. In addition, C-terminal domain shapes, which are divided into “agonist form” and “antagonist form,” were also used for clustering. We classified 27 entries of ERα into five clusters and 21 entries of ERβ into seven clusters (a total of 12 clusters). Differences in the pockets and hydrogen bonds with ligands were observed between ERα and ERβ and occurred even within the same ER species. Therefore, we conclude that the structure of ERs is diverse and is affected by ligands.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 Graduate School of Pharmacy, Meijo University, 150 Yagotoyama, Tempaku-ku, Nagoya, Aichi 468-8503, Japan; Department of Pharmacy, Kinjo Gakuin University, 2-1723 Omori, Moriyama-ku, Nagoya, Aichi 463-8521, Japan
2 Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University, Kakuma-machi, Kanazawa, Ishikawa 920-1192, Japan
3 Faculty of Pharmacy, Showa University, 1-5-8 Hatanodai, Shinagawa-ku, Tokyo 142-8555, Japan
4 Faculty of Pharmaceutical Sciences, Tohoku Medical and Pharmaceutical University, 4-4-1 Komatsushima, Aobaku, Sendai, Miyagi 981-8558, Japan
5 School of Pharmacy, Kitasato University, 5-9-1 Shirokane, Minato-ku, Tokyo 108-8641, Japan
6 Graduate School of Pharmacy, Meijo University, 150 Yagotoyama, Tempaku-ku, Nagoya, Aichi 468-8503, Japan
7 Graduate School of Pharmacy, Meijo University, 150 Yagotoyama, Tempaku-ku, Nagoya, Aichi 468-8503, Japan; Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University, Kakuma-machi, Kanazawa, Ishikawa 920-1192, Japan; Institute for Protein Research, Osaka University, 3-2 Yamadaoka, Suita, Osaka 565-0871, Japan